Shanghai RAAS Blood Products Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 1988 in Shanghai with a registered capital of RMB 6,645,480,758, Shanghai RAAS Blood Products Co., Ltd. has evolved from launching Albumin RAAS® in 1992 to a diversified blood-products leader listed on the Shenzhen Stock Exchange in 2008, operating five production bases and managing 55 plasma donation centers across 11 provinces while adhering to GMP and the Chinese Pharmacopoeia and a quality policy of 'safety, quality, and efficacy'; strategic milestones include Haier Group's acquisition of a 20% stake from Grifols for RMB 12.5 billion in 2023 and a planned-then terminated-merger in 2025, and the business generates revenue primarily from albumin, immunoglobulins and coagulation factors with quarterly revenue of RMB 2.14 billion (Q3 2025, +3.72%) and annual revenue of RMB 8.18 billion in 2024 (+2.67%), supporting a market capitalization of about RMB 43.79 billion as of December 2, 2025, while positioning itself through innovation partnerships (including work on hemophilia drugs) and recognized titles like "New High-tech Enterprise" and "Shanghai Famous Brand" to capture future demand in China's blood-products market

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): Intro

• 1988 - Shanghai RAAS Blood Products Co., Ltd. was established in Minhang Economic and Technological Development Zone, Shanghai, with a registered capital of RMB 6,645,480,758.
• 1992 - Approval of the company's first product: albumin prepared from human plasma (Albumin RAAS®).
• 1995 - Introduction/approval of multiple plasma‑derived products including virally inactivated human coagulation factor VIII (Human RAAS®), prothrombin complex concentrate (human), freeze‑dried (Prothrombin RAAS®), and human fibrinogen (Fibrinogen RAAS®).
• 1996 - First domestic liquid IV human immunoglobulin (pH4) (γ-RAAS®) approved for marketing.
• 2003 - Thrombin (human) (Thrombin RAAS®) and fibrin sealant (human) (Fibrinogen RAAS®) approved for marketing.
• 2008 - Listed on the Shenzhen Stock Exchange (stock code: 002252.SZ), a major corporate milestone unlocking wider capital markets access.

• Listed public company: trades on Shenzhen Stock Exchange under ticker 002252.SZ.
• Operates within a broader group structure (Shanghai RAAS Group and affiliated entities) that coordinates plasma collection, manufacture and distribution; majority/controlling ownership historically concentrated in group/state‑linked entities (typical for large Chinese blood‑product firms).
• Shareholder composition includes institutional investors, retail holders and related‑party/group ownership; listing has expanded institutional ownership and liquidity since 2008.

• Core mission: develop, manufacture and supply safe plasma‑derived therapeutics and hemostatic products to meet clinical demand in China and selected export markets.
• Strategic priorities historically: secure plasma sourcing, maintain GMP and viral‑safety processes, expand product portfolio (albumin, IVIG, coagulation factors, fibrin sealants), and invest in R&D and manufacturing capacity.

• Plasma collection & sourcing - collection through group‑affiliated plasma centers and contracted collection networks; sourcing volume drives raw material availability and scale.
• Fractionation & viral inactivation - industrial plasma fractionation converting plasma into multiple end products (albumin, IVIG, coagulation factors) with validated viral reduction/inactivation steps (solvent/detergent, pasteurization, low pH where applicable).
• Manufacturing & quality control - GMP‑qualified facilities producing finished sterile preparations, lot release testing, cold‑chain logistics for temperature‑sensitive biologics.
• Regulatory & pharmacovigilance - product registration with NMPA (formerly CFDA), ongoing safety surveillance and compliance with Chinese GMP and pharmacovigilance requirements.
• Sales & distribution - hospital procurement channels, provincial distributors, direct hospital tenders and, where applicable, export markets and specialty distributors.

• Albumin RAAS® (human serum albumin)
• γ-RAAS® (human immunoglobulin, liquid IV Ig pH4)
• Human RAAS® (virally inactivated coagulation factor VIII)
• Prothrombin RAAS® (prothrombin complex concentrate, freeze‑dried)
• Fibrinogen RAAS® (human fibrinogen)
• Thrombin RAAS® and Fibrin Sealant RAAS® (surgical hemostatic products)

• Product sales: primary revenue from sale of plasma‑derived therapeutics (albumin, IVIG, coagulation factors, concentrates, fibrin sealants) to hospitals and distributors.
• Scale economics: higher plasma intake and optimized fractionation improve product yields and gross margins-albumin typically generates large volume sales while IVIG and factor concentrates often carry higher per‑unit margins.
• Hospital tenders and reimbursement: selling prices and volumes are influenced by provincial hospital tender outcomes, National Reimbursement Drug List (NRDL) status, and public procurement rules.
• Export and specialty channels: incremental revenue from limited exports or specialty contract manufacturing/services where regulatory approvals permit.

• China's plasma derivatives market is led by a small group of specialized producers; scale, plasma sourcing and viral‑safety reputation are competitive advantages.
• Product mix determines margin profile: high‑volume low‑margin (albumin) vs. lower‑volume high‑margin (IVIG, coagulation factors).
• Regulatory and procurement dynamics (tenders, NRDL) materially affect pricing and hospital adoption.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): History

• Founded in 1988 in Shanghai as a privately held blood-products and biopharma company focused on plasma-derived products and biologics.
• Converted to a joint-stock company in 2007 to broaden ownership and access to capital markets.
• Listed on the Shenzhen Stock Exchange in 2008 (002252.SZ).
• In 2023 Haier Group acquired a 20% stake from Grifols for RMB 12.5 billion, becoming the largest shareholder.
• In 2024 Haier Biomedical (a Haier Group subsidiary) announced a proposed share-exchange acquisition to integrate RAAS into Haier's healthcare ecosystem.
• In 2025 the planned merger between Haier Biomedical and Shanghai RAAS was terminated due to complex transaction structures; trading of Shanghai RAAS resumed on January 7, 2025.

• Ownership structure highlights:
  • Haier Group (post-2023 purchase): 20.0% (largest shareholder)
  • Prior major shareholder: Grifols (sold 20% to Haier in 2023)
  • Public float: remaining shares traded on Shenzhen Stock Exchange (institutional and retail investors)
• Mission and business model:
  • Mission: develop, manufacture and supply plasma-derived products and biologics to meet clinical demand in China and select export markets.
  • How it makes money: commercial sales of plasma-derived therapeutics (albumin, immunoglobulins, coagulation factors), contract manufacturing, and R&D-driven product launches.
  • Revenue drivers: plasma collection scale, product mix (high-margin immunoglobulins and coagulation factors), pricing, and hospital procurement channels.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): Ownership Structure

• Mission: Provide high‑quality, safe and effective blood products to support emergency medicine and chronic disease treatment.
• Core values: Safety, quality, efficacy, innovation and social responsibility.
• Innovation focus: recombinant factor and albumin product lines; strategic R&D partnerships (e.g., Boehringer‑Ingelheim collaboration on hemophilia therapeutics).

• Major shareholder: RAAS Group (strategic controlling shareholder; industrial holding and plasma collection platforms).
• Other significant holders: institutional investors, domestic funds, and management/employee ownership through incentives.
• Listed entity: A-share on Shenzhen Stock Exchange (ticker 002252.SZ) with public float enabling market participation.

• Plasma collection and procurement: integrated sourcing from plasma centers and third‑party suppliers to secure raw plasma feedstock.
• Manufacturing: fractionation and purification to produce albumin, immunoglobulins, coagulation factors and related plasma derivatives under GMP standards.
• R&D and licensing: development of recombinant and improved formulations (including co‑development with Boehringer‑Ingelheim) to capture specialty therapeutics market.
• Sales channels: hospital procurement, national medical insurance reimbursement lists, institutional tenders and commercial distribution to clinics and pharmacies.
• Pricing and reimbursement: revenue mix driven by on‑list reimbursement for essential therapeutics and higher margins on specialty recombinant products.

• Quality compliance: GMP certification across major plants; quality incidents are rare and tightly monitored.
• Market position: Leading domestic supplier in selected plasma‑derived categories (albumin, immunoglobulin, factor concentrates).
• Social impact: Products included in national and regional emergency stocking plans and chronic disease treatment formularies.
• Brand recognition: Multi‑year recipient of 'Shanghai Famous Trademark' and 'Shanghai Famous Brand.'

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): Mission and Values

Shanghai RAAS Blood Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) positions itself as an integrated biopharmaceutical enterprise focused on plasma-derived therapeutics, promoting safe plasma collection, R&D-driven product development, standardized GMP manufacturing, and nationwide distribution. The company's stated mission centers on supplying high-quality plasma products to meet clinical needs across China while advancing technological innovation and public health safety.

• Mission: Ensure a stable, safe supply of plasma-derived medicines and improve patient outcomes through continuous R&D and quality-driven manufacturing.
• Core values: Safety, quality, innovation, compliance, and social responsibility.
• Recognition: Designated a 'New High-tech Enterprise' by the Science and Technology Commission of Shanghai Municipality, reflecting sustained investment in R&D and technology collaboration.

How It Works - Operational Footprint & Integration

Shanghai RAAS integrates source plasma collection, blood products research and development, production, and sales into a vertically coordinated model. Key operational facts:

• Production bases: Shanghai, Zhengzhou, Hefei, Wenzhou, Nanning, and Hengyang (six bases supporting manufacturing scale and regional supply).
• Plasma collection network: 55 plasma donation centers across 11 provinces - Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi, and Shandong - operated by the company and its subsidiaries.
• Quality standards: Manufacturing follows Good Manufacturing Practice (GMP) and the Chinese Pharmacopoeia; a robust quality management system underpins batch release and lot traceability.
• R&D and partnerships: Emphasis on technological innovation with international collaborations to enhance product pipelines (e.g., immunoglobulins, albumin, coagulation factors) and process technologies.

Business Model - How Shanghai RAAS Makes Money

• Plasma collection fees and processing: Revenue from collection services (source plasma) and subsequent fractionation into saleable products.
• Product sales: Major revenue drivers are plasma-derived products such as human albumin, intravenous immunoglobulin (IVIG), specific immunoglobulins, and coagulation factor concentrates supplied to hospitals, distributors, and public health institutions.
• Contract manufacturing and OEM: Production capacity enables toll manufacturing and partnerships with domestic and international firms.
• R&D-driven premium products: Higher-margin products and pipeline upgrades via technological collaboration and new indications.
• Scale advantages: Regional production bases and an extensive plasma donor network lower per-unit COGS and support supply responsiveness to clinical demand.

Quality, Compliance & Innovation

• Quality management: End-to-end quality systems cover donor screening, plasma collection, pathogen inactivation, fractionation, GMP manufacturing, and lot release.
• Regulatory alignment: Products and facilities comply with national regulatory frameworks and pharmacopoeial standards to ensure clinical safety and efficacy.
• Innovation strategy: Ongoing investment in process optimization, product formulation improvements, and collaborative R&D with international partners to expand therapeutic breadth and technical capabilities.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): How It Works

• Primary product categories: human albumin, human immunoglobulin (IVIG/SCIG), and coagulation factors (e.g., factor VIII, prothrombin complex concentrates).
• Customer segments: public and private hospitals, specialty clinics, pharmaceutical distributors, and export markets.
• Revenue model: unit sales of finished blood products (dose- or vial-based pricing), long-term procurement contracts with hospitals, tender wins for public health programs, and export sales.
• Value drivers: plasma sourcing volume and quality, production yield and capacity utilization, pricing per unit, regulatory approvals, and brand reputation.

• Sales volume x average selling price - the principal top-line driver; albumin and immunoglobulin typically command differing ASPs with immunoglobulins often higher per gram.
• Gross margins depend on plasma procurement costs (contracted collection centers or purchased plasma), manufacturing yields during fractionation, and economies of scale from large batch processing.
• Operating expenses include GMP-compliant manufacturing, cold-chain logistics for distribution, regulatory compliance, and R&D for process improvements and new indications.
• One-time/periodic contributors: capacity expansion projects, new product approvals, and export market entries that can temporarily affect margins and revenue growth rates.

• Plasma sourcing: partnerships with licensed plasmapheresis centers and purchased plasma pools.
• Testing & quarantine: serological and NAT testing, quarantine periods before pooling.
• Fractionation & purification: industrial-scale alcohol fractionation, chromatography steps for immunoglobulins, viral inactivation/removal processes.
• Formulation & fill-finish: formulation into clinical doses, aseptic filling, labeling, and batch release testing.
• Distribution & use: hospital procurement (tenders/agreements), retail distributors, and export shipments following regulatory clearance in destination countries.

• Brand strength - long-standing recognition: multiple years awarded 'Shanghai Famous Trademark' and 'Shanghai Famous Brand.'
• Technology & innovation - recognized as a 'New High-tech Enterprise' by the Science and Technology Commission of Shanghai Municipality, supporting process optimization and product development.
• Regulatory landscape - domestic NMPA approvals and compliance with international GMP standards influence market access and pricing power.
• Market dynamics - demand driven by aging population, immunodeficiency and bleeding disorders management, and hospital procurement budgets.

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ): How It Makes Money

• Core revenue streams: plasma-derived therapeutics (IVIG, albumin, human coagulation factors), contract manufacturing and bulk plasma product sales to hospitals and distributors.
• Adjunct revenue: plasma collection service fees, exports of intermediate products, and licensing/technology services.
• High-margin portfolio: specialty products such as IVIG and coagulation concentrates typically deliver higher gross margins than bulk albumin.

• Market leader in China's plasma products sector with broad product coverage (IVIG, albumin, factor VIII/IX, hyperimmune globulins) and multiple production sites enabling scale and supply resilience.
• Operational efficiency: reported plasma utilization rates among the industry's highest (historically in the 70-85% range), improving yields per litre of plasma and lowering unit costs.
• Brand & tech credentials: repeatedly recognized as a "New High-tech Enterprise" by the Shanghai Science and Technology Commission and awarded "Shanghai Famous Trademark" / "Shanghai Famous Brand," reinforcing trust among institutional buyers and regulators.

• Plasma collection network: collects plasma through company-run centers and third-party agreements; this captive plasma supply reduces procurement volatility and secures raw material for high-value products.
• Fractionation & formulation: vertical integration allows conversion of raw plasma into multiple finished products, increasing revenue per litre of plasma and enabling flexible product mix based on demand/pricing.
• Pricing & reimbursement: sales to hospitals and public medical procurement platforms backed by national and regional reimbursement policies; pricing power for specialty indications helps sustain margins.
• Scale-driven cost leverage: increasing production volumes dilute fixed costs (facility, QC, regulatory) and support incremental margin expansion.

• Demand tailwinds: aging population and broader indications for immunoglobulins and coagulation therapies support secular volume growth.
• Capacity expansion: planned upgrades and new fractionation lines are expected to raise output and product mix toward higher-margin specialty biologics.
• R&D and value-added products: recognition as a high-tech enterprise underpins continued investment in biologics R&D, biosimilar programs and improved fractionation technologies to sustain long-term competitiveness.
• Export potential and partnerships: selective international sales of intermediates and finished products, plus contract manufacturing opportunities, can diversify revenue and improve utilization.